Ironwood Pharmaceuticals Announces Positive Results from its Phase II Exploratory STARGAZE Trial of Apraglutide in Patients with Steroid-Refractory Gastrointestinal Acute Graft-versus-Host Disease (SR GI aGVHD)

https://investor.ironwoodpharma.com/press-releases/press-release-details/2024/Ironwood-Pharmaceuticals-Announces-Positive-Results-from-its-Phase-II-Exploratory-STARGAZE-Trial-of-Apraglutide-in-Patients-with-Steroid-Refractory-Gastrointestinal-Acute-Graft-versus-Host-Disease-SR-GI-aGVHD/default.aspx

Ironwood has successfully completed the tender offer of VectivBio, a global clinical-stage biotechnology company
pioneering novel, transformational treatments for severe rare gastrointestinal conditions. For more information, click here